Clinical & Experimental Immunology · 1994 · 46 citations · 12 references
Life SciencesImmunologyPharmacologyCellular ImmunologyImmunopharmacologyImmunoregulationB Cell ActivationB Cell BiologyB-cell ResponsesHumoral ImmunityImmunoglobulin FunctionLymphocyte ActivationActivated B Cell ResponsesDirect EffectsImmunoglobulin G ResponsesImmunoglobulin Production
In order to assess the direct effects of cyclosporine A (CsA) and rapamycin on B cells, we utilized a two-segment culture system of highly purified B lymphocytes consisting of induction (activation) in the presence of the formalinized Staphylococcus aureus bacteria and IL-2, and differentiation, respectively, in the presence of various combinations of cytokines. Results show that rapamycin strongly inhibited production of both IgM and IgG measured at the end of the secondary culture supported by IL-2/IL-6, whereas CsA up-regulated the immunoglobulin production. The stimulatory effect of CsA was also observed when preactivated B cells were recultured in absence of any cytokines. These results show that rapamycin and CsA have clearly distinct effects on human B lymphocyte responses in vitro. Rapamycin is a more potent in vitro immunosuppressant of B lymphocytes than CsA. It is effective at significantly lower concentrations, and it does not stimulate either the proliferation or antibody production by preactivated B cells.
12
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Jun S. Liu, Jesse D. Farmer, Willam S. Lane et al. · Cell · 1991 · 4.1K citations
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins
Günter Fischer, Brigitte Wittmann‐Liebold, Kurt Lang et al. · Nature · 1989 · 1.4K citations
Barbara E. Bierer, Petri S. Mattila, Robert F. Standaert et al. · Proceedings of the National Academy of Sciences · 1990 · 708 citations
Kidney Transplantation Under FK 506
T. E. Starzl · JAMA · 1990 · 234 citations
Medicine, Immunology, Pharmacology +17